Miriam Merad
Miram Merad (born in Paris in 1969)[1] is an Algerian professor in Cancer immunology and the Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai in New York City, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology[2] and a member of the United States National Academy of Sciences.[3]
Miriam Merad | |
---|---|
Born | Paris, France |
Education | Algiers 1 University Stanford University |
Scientific career | |
Fields | Immunology |
Institutions | Icahn School of Medicine at Mount Sinai |
Career
Miriam Merad started her medical school at the University of Algiers in 1985 and completed her residency in Paris Diderot University.[4] She then moved to Stanford University to perform a phD in the laboratory of Edgar Engleman.[5] She was first recruited to the Icahn School of Medicine at Mount Sinai in 2004 and promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010. She obtained an Endowed Chair in Cancer Immunology in 2014.[6]
Research
Miram Merad's early studies were among the first to identify the mechanisms that control the development and functional identity of tissue resident dendritic cells and macrophages. Current research in her lab remains focused on the role dendritic cells and macrophages play within the tumor microenvironment and on how tumors prevent the normal anti-tumor functions of these cells.[7]
Honors
- Vice-President of the International Union of Immunological Societies.[8]
- Member of the American Society for Clinical Investigation.[9]
- William B. Coley Award for Distinguished Research in Tumor Immunology[10]
- Member of the United States National Academy of Sciences.[11]
Notable publications
- Merad, M; Manz, MG; Karsunky, H; Wagers, A; Engleman, EG (2002). "Langerhans cells renew in the skin throughout life under steady-state conditions". Annu Rev Immunol. 3: 1135–1141. doi:10.1038/ni852. PMC 4727838. PMID 12415265.
- Ginhoux, F; Greter, M; Leboeuf, M; Nandi, S; Merad, M (2010). "Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages". Science. 330: 841–845. doi:10.1126/science.1194637. PMC 3719181. PMID 20966214.
- Merad, M; Sather, P; Helft, J; Miller, J; Mortha, A (2013). "The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting". Annu Rev Immunol. 31: 563–604. doi:10.1146/annurev-immunol-020711-074950. PMC 3853342. PMID 23516985.
- Hashimoto, D; Chow, A; Noizat, C; Teo, P; Merad, M (2013). "Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes". Immunity. 38: 792–804. doi:10.1016/j.immuni.2013.04.004.
- Lavin, Y; Winter, D; Blecher-Gonen, R; David, E; Merad, M (2014). "Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment". Cell. 159: 1312–1326. doi:10.1016/j.cell.2014.11.018.
References
- "Cancer Vaxxer: A Profile of Miriam Merad". the-scientist.com. Retrieved 31 May 2019.
- "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Retrieved 31 May 2019.
- "2020 NAS Election". www.nasonline.org. Retrieved 28 April 2020.
- "miriam-merad, MD, PhD". icahn.mssm.edu. Retrieved 3 June 2019.
- "Engleman Trainees 1983-present" (PDF). Retrieved 3 June 2019.
- "miriam-merad, MD/PhD". icahn.mssm.edu. Retrieved 3 June 2019.
- "Cancer Vaxxer: A Profile of Miriam Merad". the-scientist.com. Retrieved 31 May 2019.
- "International Union of Immunological Societies". Retrieved 20 February 2020.
- "The American Society for Clinical Investigation". Retrieved 3 June 2019.
- "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Retrieved 31 May 2019.
- "2020 NAS Election". www.nasonline.org. Retrieved 28 April 2020.